Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,404,653
  • Shares Outstanding, K 1,092,089
  • Annual Sales, $ 16,887 M
  • Annual Income, $ -16,265,000 K
  • 60-Month Beta 1.84
  • Price/Sales 0.86
  • Price/Cash Flow 2.88
  • Price/Book 0.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.56
  • Number of Estimates 5
  • High Estimate 0.62
  • Low Estimate 0.50
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -1.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.54 +38.26%
on 01/27/20
13.76 -4.14%
on 02/12/20
+3.17 (+31.64%)
since 01/21/20
3-Month
8.77 +50.48%
on 01/13/20
13.76 -4.14%
on 02/12/20
+2.94 (+28.68%)
since 11/21/19
52-Week
6.07 +117.30%
on 08/15/19
17.90 -26.31%
on 02/25/19
-4.06 (-23.54%)
since 02/21/19

Most Recent Stories

More News
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates

Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.

TEVA : 13.19 (-0.90%)
SNY : 50.85 (+0.20%)
PRGO : 59.86 (+0.42%)
EBS : 65.94 (+2.11%)
3 Best Drugmakers That Are Immune to Coronavirus Fright

The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

JNJ : 149.93 (+1.05%)
TEVA : 13.19 (-0.90%)
PFE : 35.72 (-0.36%)
MYL : 21.15 (+1.08%)
BAYRY : 20.0699 (-0.79%)
Global Acne Drugs Market Expected to Deliver Dynamic Progression until 2029| Johnson & Johnson, Nestle S.A. (Galderma S.A.) and Allergan Plc

Global Acne Drugs Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property Analysis, Market Attractiveness,...

GSK : 43.08 (+0.75%)
MAYNF : 0.2625 (-5.54%)
PFE : 35.72 (-0.36%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Phase 2/3 ARTISTS 1 and Phase 3 ARTISTS 2 trials designed to evaluate deutetrabenazine compared to placebo for the treatment...

TEVA : 13.19 (-0.90%)
Myasthenia Gravis Treatment Market: Global Industry Analysis and Opportunity Assessment 2019-2025

Myasthenia Gravis Treatment Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate...

ABBV : 94.96 (+0.77%)
GSK : 43.08 (+0.75%)
NVS : 96.76 (+0.49%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Global Acute Kidney Injury Treatment Market Provides An In-Depth Insight Of Sales Analysis| Pfizer Inc, Ipsen SA and Novartis AG

Global Acute Kidney Injury Treatment Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual Property...

CNAT : 0.47 (+7.06%)
IPSEY : 18.1700 (+0.94%)
MRK : 82.34 (-0.18%)
NVS : 96.76 (+0.49%)
PFE : 35.72 (-0.36%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Ophthalmic Drugs Market Size Is Estimated To Expand at a CAGR of 6% By 2025

AGN : 200.15 (+0.71%)
MRK : 82.34 (-0.18%)
PFE : 35.72 (-0.36%)
REGN : 403.15 (+1.00%)
SNPHF : 19.3000 (-0.26%)
SHPG : 179.20 (+4.10%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Pharmaceutical Contract Manufacturing Market - Big Changes to Have Big Impact

HTF MI added a new research study in its database with title 'Global Pharmaceutical Contract Manufacturing Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025'...

TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize

Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.

TEVA : 13.19 (-0.90%)
RHHBY : 44.0300 (+0.39%)
AGN : 200.15 (+0.71%)
EGRX : 52.17 (-0.25%)
Drug Makers Focusing on Pain Management Alternatives to Opioid Drugs

Opioid drugs are and have been a God-send for many patients whose severe, excruciating pain had no other drug or device to allow them to escape from its throes... But we all know that the other side of...

QBIO : 3.1600 (-8.41%)
COLL : 23.93 (+1.36%)
MNK : 5.12 (-0.78%)
ENDP : 6.07 (-0.65%)
TEVA : 13.19 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade TEVA with:

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 13.46
1st Resistance Point 13.33
Last Price 13.19
1st Support Level 13.05
2nd Support Level 12.90

See More

52-Week High 17.90
Fibonacci 61.8% 13.38
Last Price 13.19
Fibonacci 50% 11.98
Fibonacci 38.2% 10.59
52-Week Low 6.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar